Department of Epidemiology, UCLA, Fielding School of Public Health, Los Angeles, CA, 90095-1772, USA.
Department of Biostatistics, UCLA, Fielding School of Public Health, Los Angeles, CA, USA.
Lipids Health Dis. 2022 Jul 27;21(1):63. doi: 10.1186/s12944-022-01668-0.
To assess the long-term biological coefficient of variation within individuals (CV) and between individuals (CV), effect of aging and cholesterol lowering drugs on blood levels of lipids in HIV-1-infected and -uninfected men.
Bloods were analyzed every six months over 17 years for total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) in 140 HIV-uninfected (38-66 years old) and 90 HIV-treated infected (48-64 years old) white Caucasian men to examine CV, CV, and the effect of cholesterol lowering drugs (CLDs) on lipid levels, and estimated changes per year of biomarkers.
With exception of HDL-C, the long term CV compared with CV were higher for serum levels of TC, TGs, and LDL-C in both HIV-1 infected and uninfected men not taking CLDs. Excluding results of TGs in HIV positive men, the CV compared with CV were lower for serum levels of TC, HDL-C, and LDL-C in both groups not taking CLDs. There were significant (p < 0.05) differences in the median serum values of lipid biomarkers among 77 HIV negative men taking and 63 not taking CLDs. Also, with exception of HDL, there were significant (p < 0.05) differences in the median values of TC, TGs and LDL-C among 28 HIV positive men taking or not taking CLDs.
Long term CV and CV of biomarkers will be useful for monitoring antiviral therapy side effects on lipid profiles in HIV-infected men. CV of HIV-infected men for TC, TGs, HDL, LDL were higher significantly than CV of HIV-uninfected men. Interestingly the long term CV were higher than CV for the men, who were on CLDs compared to men not on CLDs. The long-term pattern of CV and CV of lipid markers in both HIV-infected and uninfected men on CLDs differed from their short-term pattern.
评估个体内（CV）和个体间（CV）的长期生物学变异系数，以及衰老和降胆固醇药物对 HIV-1 感染和未感染男性血液中脂质水平的影响。
在 17 年的时间里，每 6 个月对 140 名未感染 HIV 的男性（38-66 岁）和 90 名接受 HIV 治疗的感染男性（48-64 岁）的总胆固醇（TC）、甘油三酯（TGs）、高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）进行分析，以检查 CV、CV 和降胆固醇药物（CLDs）对脂质水平的影响，并估计每年生物标志物的变化。
除 HDL-C 外，未服用 CLD 的 HIV-1 感染和未感染男性的 TC、TGs 和 LDL-C 血清水平的长期 CV 均高于 CV。排除 HIV 阳性男性的 TGs 结果，未服用 CLD 的两组人群 TC、HDL-C 和 LDL-C 的 CV 均低于 CV。77 名未服用 CLD 的 HIV 阴性男性和 63 名未服用 CLD 的男性的血脂生物标志物血清值中位数存在显著差异（p<0.05）。此外，除 HDL 外，28 名服用或未服用 CLD 的 HIV 阳性男性的 TC、TGs 和 LDL-C 的中位数值也存在显著差异（p<0.05）。
长期 CV 和 CV 可用于监测 HIV 感染男性抗病毒治疗对血脂谱的副作用。与 HIV 未感染男性相比，TC、TGs、HDL 和 LDL 的 HIV 感染男性 CV 显著更高。有趣的是，与未服用 CLD 的男性相比，服用 CLD 的男性的长期 CV 高于 CV。在服用 CLD 的 HIV 感染和未感染男性中，CV 和脂质标志物的长期模式与短期模式不同。
